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Introduction {#sec005}
============

Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a rare, life threatening hyperinflammatory syndrome characterized by excessive activation of histiocytes and T lymphocytes leading to highly active but ineffective immune response \[[@pone.0226899.ref001]\]. HLH is classified into primary and secondary forms. Primary HLH is associated with different genetic defects in cytotoxic pathway that typically occur before age 18 but has been described in adults up to age 60 \[[@pone.0226899.ref002]\]. In contrast, secondary or acquired HLH is seen in adults who have no underlying family history, showing however other underlying conditions which can induce strong immunological stimulation, such as haematological or solid malignancies, infections, rheumatic diseases and autoimmune diseases \[[@pone.0226899.ref003]\]. Infections associated with HLH are most frequently caused by viruses (e.g. Epstein-Barr, Cytomegalovirus, Herpes simplex), but bacterial, fungal, and parasites have also been described \[[@pone.0226899.ref004]\]. HLH symptoms may initially mirror those observed in an infection (fever, malaise and fatigue). However, in patients with HLH the subsequent hyperinflammatory response is fatal in a high percentage of cases if left untreated (50--100% depending on the underlying condition) \[[@pone.0226899.ref001]\]. Diagnosing HLH is the critical step toward successful therapy, which is currently based on corticosteroids associated with other immunosuppressant drugs \[[@pone.0226899.ref005]\].

Despite increasing insights into its genetic and immunologic basis \[[@pone.0226899.ref005]\]\], HLH is still diagnosed based on a combination of clinical and laboratory findings ([Table 1](#pone.0226899.t001){ref-type="table"}).

10.1371/journal.pone.0226899.t001

###### Diagnostic criteria for HLH used in the HLH-2004 trial[\*](#t001fn001){ref-type="table-fn"}.

The diagnosis of HLH is established when 5 of the 8 criteria listed below are fulfilled.

![](pone.0226899.t001){#pone.0226899.t001g}

  ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  1\. Fever                                                                                 ≥ 38.5°C

  2\. Splenomegaly                                                                          

  3\. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood)               Hemoglobin \< 9 g/dL; Platelets \< 100 x 10^3^/mL; Neutrophils \< 1 x 10^3^/mL

  4\. Hypertriglyceridemia and/or hypofibrinogenemia                                        fasting, \> 265 mg/dL\
                                                                                            \<150 mg/dL

  5\. Hemophagocytosis                                                                      in bone marrow, spleen, lymph nodes, or liver

  6\. Low or absent NK-cell activity                                                        

  7\. Ferritin                                                                              \> 500 μg/L [‡](#t001fn003){ref-type="table-fn"}

  8\. Elevated sCD25 (alpha-chain of sIL-2 receptor) [§](#t001fn004){ref-type="table-fn"}   
  ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------

\*modified from Henter et al. \[[@pone.0226899.ref006]\]\]

Notes

‡Although the HLH-2004 protocol uses ferritin \> 500 μg/L, higher values should prompt a higher clinical suspicion, namely ferritin \> 3000 μg/L might be seen as suspicious of HLH and ferritin \> 10 000 μg/L as highly suspicious for HLH.

§Elevations above age-adjusted, laboratory-specific normal levels (defined as \> 2 SD from the mean) appear more meaningful than the original designation of \>2400 U/mL because of variations between laboratories.

Many of these findings are nonspecific and are commonly observed systemic inflammatory response syndrome. In a landmark prospective international treatment study of HLH in children, the Histiocyte Society suggested five diagnostic criteria: fever, splenomegaly, bicytopenia (neutro- and thrombocytopenia), hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis in target organs (bone marrow, liver, spleen and lymph nodes) \[[@pone.0226899.ref007]\]. Subsequently, three additional criteria have been added \[[@pone.0226899.ref006]\]: hyperferritinemia, low/absent NK-cell-activity, and high-soluble interleukin-2-receptor (CD25) levels. Among the eight criteria, five must be fulfilled to diagnose HLH according to the HLH-2004 guidelines \[[@pone.0226899.ref006]\].

These criteria have been developed to diagnose HLH in children, but are usually adopted in adults as well since no specific study is available \[[@pone.0226899.ref008], [@pone.0226899.ref009]\]. In particular it has been suggested that ferritin levels above 10,000 μg /L are accurate for HLH diagnosis, and could be used to prompt further tests in adults \[[@pone.0226899.ref010]\]; this has been recently questioned \[[@pone.0226899.ref011]\] and hyperferritinemia alone should never be used to diagnose HLH. Special tests such as NK cell function (no longer done routinely) and soluble CD25 (alpha chain of the IL-2 receptor, marker of T-cell activation) as well as sCD163 (marker of macrophage activation) and CD107a (marker of degranulation) which more consistently correlated with the disease activity \[[@pone.0226899.ref009]\] are not available in all laboratories and cannot be usually immediately obtained. Therefore, treatment delay is frequent.

Despite the fact that elevated liver enzymes are found in 98% of cases of HLH \[[@pone.0226899.ref012]\], little is known regarding liver-related aspects of HLH in adults. Some cases presenting as acute hepatitis have been reported \[[@pone.0226899.ref013], [@pone.0226899.ref014]\], and occasionally, acute liver failure (ALF) may dominate the clinical presentation \[[@pone.0226899.ref015], [@pone.0226899.ref016]\].

Liver biopsy can reveal activated macrophages with hemophagocytosis (any hemopoietic cell included in the histiocyte, but most typically red cells and/or platelets) \[[@pone.0226899.ref017]\]. In primary, pediatric forms of HLH, liver histopathology shows a characteristic pattern with a portal and sinusoidal infiltrate of CD3+, CD8+, granzyme B+ lymphocytes admixed with CD68+, CD1a- (benign but activated) histiocytes that exhibit hemophagocytosis \[[@pone.0226899.ref018], [@pone.0226899.ref019]\]. Typically, endothelialitis of portal and central veins and lymphocyte-mediated bile duct injury is observed, and the degree of portal and sinusoidal lympho-histiocytic infiltrate and endothelialitis varies from mild to marked and correlates with clinical severity \[[@pone.0226899.ref017]\]. Interestingly, in one autoptic study conducted in children with primary HLH, bone marrow biopsy was often negative, while liver biopsy consistently showed "chronic hepatitis like" portal lymphocyte infiltrate, suggesting that findings at liver biopsy might be more sensitive for the diagnosis of HLH \[[@pone.0226899.ref019]\].

Given the disease's nonspecific feature, its diagnosis in patients presenting with liver involvement is difficult and requires exclusion of more common conditions and histological confirmation.

On the other hand, in patients presenting with acute liver disease, but lacking the classical clinical diagnostic criteria of HLH syndrome, histological findings of sinusoidal hemophagocytosis are occasionally seen on liver biopsy and are considered non-specific for HLH \[[@pone.0226899.ref020]\], but the clinical relevance of these findings is largely unclear.

The purpose of this study is to describe the clinical features and outcomes of patients consecutively admitted in our center in the period 08/2011-08/2017 in whom liver histology showed sinusoidal hemophagocytosis (irrespective of whether HLH was eventually diagnosed). We aimed to compare patients' clinical characteristics in those with and without secondary HLH according to the established HLH diagnostic criteria. Furthermore, we evaluated in how many of our adult cases the presence of sinusoidal hemophagocytosis on liver biopsy was a valuable additional diagnostic criterion.

Materials and Methods {#sec006}
=====================

This was a single center, retrospective study conducted at Inselspital, University of Bern, Switzerland, in adult patients. This study has been approved by the Ethic Committee of the Canton of Bern (KEK-BE: 2017--00148) and informed consent was not required. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Cases were identified and collected in a 6 year period, from 08/2011 to 08/2017 by accessing the Pathology Institute of the University of Bern (electronic record system last accessed on August 10, 2017) identifying cases showing sinusoidal hemophagocytosis on liver histology; and by reviewing all adult patients with critically ill disease presenting with severe liver disease (MELD score \[[@pone.0226899.ref021]\] ≥15 and/or Child-Pugh class C) in whom HLH was histologically confirmed on any tissue (recorded at the hepatology unit of our center). Clinical, radiological and laboratory data were retrieved from the electronic record system of Inselspital (CGM Phoenix, Compu Group Medical Schweiz, AG). We retrospectively reviewed the patients' medical records and retrieved information regarding their underlying diseases, possible triggers of hemophagocytosis, clinical features, laboratory data, treatment and outcome. We assessed the criteria recommended by the Histiocyte Society ([Table 1](#pone.0226899.t001){ref-type="table"}) and calculated the Score of Saint Antoine (Hscore) \[[@pone.0226899.ref022]\] using the online calculator: <http://saintantoine.aphp.fr/score/>. Furthermore, we evaluated the presence of sinusoidal hemophagocytosis as possible additional diagnostic criterion to be used in adults. Soluble CD25 and NK were not quantified in the presented patients. On liver biopsy samples, the presence of sinusoidal hemophagocytosis was reviewed by a single experienced pathologist. Ascertained by haematoxylin and eosin (HE) staining; quantification of number of foci of hemophagocytosis per 20x field was performed. Immunohistochemistry CD68 staining was made to better identify activated macrophages. The number of CD68 positive macrophages per high power field was determined.

Cases of primary HLH were excluded from this analysis.

Statistical analysis {#sec007}
--------------------

Numerical data are described using median, interquartile range (IQR) and range, and percentages are given when required. Non-parametric tests were used to compare numerical parameters, and to obtain correlations between clinical and laboratory parameters and findings on histology. All tests are 2-sided and p\<0.05 was considered significant. Statistical analysis was performed using PAWS statistics version 23 for Windows (SPSS Inc, Chicago, IL, USA).

Results {#sec008}
=======

We identified 12 cases with liver histology showing sinusoidal hemophagocytosis. Most of them were male (58%). The median age was 61 (IQR 26; range 22--81) years old. Seven patients (58%) were older than 70. Ten patients (83%) had an underlying chronic disease, which in 2 cases was diagnosed during the hospital admission.

[Table 2](#pone.0226899.t002){ref-type="table"} summarizes the clinical and laboratory features of the study population.

10.1371/journal.pone.0226899.t002

###### Clinical, laboratory and histological characteristics of the included patients.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                             HLH diagnostic criteria fulfilled before liver biopsy                                                                                                     HLH diagnostic criteria fulfilled\                                                                                            Sinusoidal hemophagocytosis, but diagnostic criteria\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                       on liver biopsy                                                                                                               of HLH not fulfilled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------- -----------------------------------------------------------------------------
  **Underlying chronic disease**                                             Pancolitis interpreted as ulcerative colitis, on immunosuppressive therapy                                                                                Chronic lymphocitic leukemia and Evans Syndrome                                                                               Anaplastic lymphoma (diagnosed during the hospitalisation)   Systemic lupus erythemathodes and secondary antiphospholipid syndrome                                                None                                                      Pure white cell aplasia                                                                                                                                                                                                Evans Syndrome\                                                                                                                 Alcoholic cirrhosis and portal hypertension (large varices)                                    Evans syndrome/ granulomatous vasculitis; chronic liver disease with septal and porto-portal fibrosis (unclear origin)            None                          T cell Lymphoma                                                 Autoimmune hepatitis (diagnosed on liver biopsy during the hospitalisation)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (Possible autoimmune hepatitis identified on biopsy)                                                                                                                                                                                                                                                                                                                                                                                                           

  **Possible infectious trigger for HLH**                                    CMV infection                                                                                                                                             None identified                                                                                                               S.aureus sepsis                                              Pancolitis of unclear origin                                                                                         Bacterial pneumonia                                       Perianal abscess and bilateral pneumonia due to Pseudomonas aeruginosa                                                                                                                                                 None identified                                                                                                                 Suspected hemolytic-uremic syndrome                                                            CMV infection                                                                                                                     None identified               None identified                                                 None identified

  **Type of presentation**                                                   High fever and pancytopenia + progressive increase of LFTs. Bone marrow biopsy negative.                                                                  High fever, pancytopenia and worsening of the general status in the last 3 weeks (following a bone marrow biopsy, negative)   Jaundice and MOF                                             High fever and pancytopenia, followed by spontaneous retroperitoneal hematoma on the second day of hospitalisation   High fever and increased LFTs since 1 week                High fever and pancytopenia + cholestasis interpreted as sepsis; three bone marrow biopsies in the weeks before hospitalisation were negative                                                                          Pancytopenia, high fever and elevated LFTs since 1 month; hepatosplenomegaly and lymphadenopathy; bone marrow biopsy negative   Diarrhea with lower GI bleeding, pancytopenia and coma interpreted as hepatic encephalopathy   Chronic elevation of LFTs and ascites                                                                                             FUO, elevated liver enzymes   Jaundice and anemia                                             Jaundice and increased LFTs associated with polyarthralgias

  hemolytic anemia non responsive to high doses of prednisone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Severely ill patient**                                                   Yes                                                                                                                                                       Yes                                                                                                                           Yes                                                          Yes                                                                                                                  No                                                        Yes                                                                                                                                                                                                                    No                                                                                                                              Yes                                                                                            No                                                                                                                                No                            No                                                              No

  ***Clinical criteria of HLH***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Fever \>38.5°**                                                          \+                                                                                                                                                        \+                                                                                                                            \+                                                           \+                                                                                                                   \+                                                        \+                                                                                                                                                                                                                     \+                                                                                                                              ─                                                                                              ─                                                                                                                                 \+                            ─                                                               ─

  **Splenomegaly**                                                           \+                                                                                                                                                        \+                                                                                                                            \+                                                           ─                                                                                                                    \+                                                        \+                                                                                                                                                                                                                     \+                                                                                                                              \+                                                                                             \+                                                                                                                                \+                            ─                                                               ─

  **Bicytopenia**                                                            \+                                                                                                                                                        \+                                                                                                                            \+                                                           \+                                                                                                                   ─                                                         \+                                                                                                                                                                                                                     \+                                                                                                                              \+                                                                                             ─                                                                                                                                 ─                             ─                                                               ─

  **Hypertriglyceridemia and/or hypofibrinogenemia**                         \+                                                                                                                                                        \+                                                                                                                            \+                                                           \+                                                                                                                   \+                                                        TG not measured/                                                                                                                                                                                                       TG not measured/                                                                                                                ─                                                                                              \+                                                                                                                                TG not measured/              ─                                                               ─

  Fibrinogen normal                                                          Fibrinogen normal                                                                                                                                         Fibrinogen normal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Hyperferritinemia**                                                      \+                                                                                                                                                        \+                                                                                                                            \+                                                           \+                                                                                                                   \+                                                        \+                                                                                                                                                                                                                     \+                                                                                                                              \+                                                                                             \+                                                                                                                                \+                            \+                                                              \+

  **EBV Status**                                                             IgG not performed,\                                                                                                                                       IgG positive,\                                                                                                                IgG positive, IgM negative                                   Not available                                                                                                        IgG positive, IgM negative                                IgG positive, IgM negative                                                                                                                                                                                             IgG positive, IgM negative, EBV in situ hybridization negative                                                                  IgG positive, IgM negative\                                                                    IgG positive, IgM negative                                                                                                        Not available                 IgG positive, IgM negative                                      Not available
                                                                             PCR negative                                                                                                                                              PCR negative                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PCR negative                                                                                                                                                                                                                                                                                                                   

  **Hemophagocytosis on histology**                                          \+                                                                                                                                                        \+                                                                                                                            \+                                                           \+                                                                                                                   \+                                                        \+                                                                                                                                                                                                                     \+                                                                                                                              \+                                                                                             \+                                                                                                                                \+                            \+                                                              \+

  **N criteria fulfilled before liver biopsy**                               5                                                                                                                                                         5                                                                                                                             5                                                            4                                                                                                                    4                                                         4                                                                                                                                                                                                                      4                                                                                                                               3                                                                                              3                                                                                                                                 3                             1                                                               1

  **N criteria fulfilled after liver biopsy**                                6                                                                                                                                                         6                                                                                                                             6                                                            5                                                                                                                    5                                                         5                                                                                                                                                                                                                      5                                                                                                                               4                                                                                              4                                                                                                                                 4                             2                                                               2

  ***Other relevant clinical findings***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Ascites (none/moderate/severe)**                                         none                                                                                                                                                      none                                                                                                                          none                                                         none                                                                                                                 none                                                      none                                                                                                                                                                                                                   none                                                                                                                            severe                                                                                         moderate                                                                                                                          N/A                           moderate                                                        none

  ***Biochemistry at presentation***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Hemoglobin, g/L**                                                        70                                                                                                                                                        73                                                                                                                            89                                                           77                                                                                                                   135                                                       75                                                                                                                                                                                                                     63                                                                                                                              78                                                                                             71                                                                                                                                129                           77                                                              147

  **Platelet count, x 10**^**9**^**/L**                                      11                                                                                                                                                        24                                                                                                                            84                                                           1                                                                                                                    342                                                       91                                                                                                                                                                                                                     2                                                                                                                               15                                                                                             116                                                                                                                               normal                        263                                                             143

  **White cells (neutrophils), x 10**^**9**^**/L**                           1                                                                                                                                                         0.77                                                                                                                          0.089                                                        3.29                                                                                                                 8.84                                                      0.01                                                                                                                                                                                                                   N/A                                                                                                                             0.69                                                                                           9.89                                                                                                                              normal                        4.2                                                             5.08

  **Serum ferritin, mg/L (15--300)**                                         16000                                                                                                                                                     110000                                                                                                                        18000                                                        12684                                                                                                                1600                                                      1590                                                                                                                                                                                                                   733                                                                                                                             4031                                                                                           7380                                                                                                                              1394                          24905                                                           9441

  **AST/ALT, U/L (38/40)**                                                   283/183                                                                                                                                                   340/306                                                                                                                       350/364                                                      49/43                                                                                                                48/77                                                     31/31                                                                                                                                                                                                                  176/112                                                                                                                         181/63                                                                                         42/23                                                                                                                             N/A                           183/185                                                         1187/2243

  **Bilirubin, mmol/L (\<17)**                                               66                                                                                                                                                        19                                                                                                                            17                                                           4                                                                                                                    36                                                        40                                                                                                                                                                                                                     127                                                                                                                             270                                                                                            98                                                                                                                                N/A                           1038                                                            200

  **ALP, U/L**                                                               321                                                                                                                                                       250                                                                                                                           532                                                          111                                                                                                                  123                                                       167                                                                                                                                                                                                                    157                                                                                                                             112                                                                                            78                                                                                                                                N/A                           509                                                             172

  **GGT, U/L**                                                               370                                                                                                                                                       198                                                                                                                           640                                                          166                                                                                                                  151                                                       248                                                                                                                                                                                                                    242                                                                                                                             151                                                                                            53                                                                                                                                N/A                           1105                                                            227

  **Albumin, G/L (\>35)**                                                    20                                                                                                                                                        28                                                                                                                            29                                                           20                                                                                                                   28                                                        11                                                                                                                                                                                                                     19                                                                                                                              23                                                                                             24                                                                                                                                N/A                           34                                                              24

  **INR (1.00)**                                                             1.26                                                                                                                                                      2.2                                                                                                                           2.6                                                          2.94                                                                                                                 1                                                         1.2                                                                                                                                                                                                                    1.2                                                                                                                             1.58                                                                                           1.4                                                                                                                               N/A                           1.13                                                            1.35

  **Creatinine, mmol/L**                                                     199                                                                                                                                                       74                                                                                                                            70                                                           485                                                                                                                  86                                                        127                                                                                                                                                                                                                    42                                                                                                                              228                                                                                            76                                                                                                                                N/A                           122                                                             58

  ** Hscore**                                                                 236                                                                                                                                                       221                                                                                                                           192                                                          228                                                                                                                 119                                                       127                                                                                                                                                                                                                    132                                                                                                                             190                                                                                            169                                                                                                                               90                            167                                                             102

  ***Biochemistry---maximal value***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **AST/ALT, U/L (38/40)**                                                   350/204                                                                                                                                                   3914/1196                                                                                                                     357/364                                                      159/30                                                                                                               114/188                                                   33/31                                                                                                                                                                                                                  176/112                                                                                                                         1966/1016                                                                                      167/68                                                                                                                            N/A                           183/185                                                         1319/2310

  **Bilirubin, mmol/L (\<17)**                                               293                                                                                                                                                       56                                                                                                                            186                                                          58                                                                                                                   36                                                        343                                                                                                                                                                                                                    127                                                                                                                             270                                                                                            1070                                                                                                                              N/A                           1038                                                            260

  **ALP, U/L**                                                               321                                                                                                                                                       425                                                                                                                           532                                                          197                                                                                                                  323                                                       263                                                                                                                                                                                                                    157                                                                                                                             384                                                                                            78                                                                                                                                N/A                           509                                                             172

  **GGT, U/L**                                                               370                                                                                                                                                       599                                                                                                                           640                                                          483                                                                                                                  322                                                       293                                                                                                                                                                                                                    242                                                                                                                             151                                                                                            53                                                                                                                                N/A                           1105                                                            240

  ***Time from hospital admission to biopsy*, *days***                       12                                                                                                                                                        5                                                                                                                             2                                                            21                                                                                                                   9                                                         25                                                                                                                                                                                                                     16                                                                                                                              6                                                                                              21                                                                                                                                10                            1                                                               2

  ***N foci of hemophagocytosis in liver biopsy (per 20x magnification)***   15                                                                                                                                                        20                                                                                                                            20                                                           22                                                                                                                   8                                                         10                                                                                                                                                                                                                     15                                                                                                                              N/A                                                                                            11                                                                                                                                22                            N/A                                                             50

  **Sinusoidal dilatation**                                                  absent                                                                                                                                                    absent                                                                                                                        absent                                                       present                                                                                                              present                                                   absent                                                                                                                                                                                                                 absent                                                                                                                          N/A                                                                                            present                                                                                                                           present                       absent                                                          absent

  **Liver fibrosis**                                                         absent                                                                                                                                                    absent                                                                                                                        absent                                                       absent                                                                                                               absent                                                    absent                                                                                                                                                                                                                 low grade, non-septal                                                                                                           N/A                                                                                            present, septal                                                                                                                   absent                        absent                                                          absent

  **Lobular necrosis**                                                       present (centrolobular)                                                                                                                                   present (centrolobular)                                                                                                       absent                                                       present (centrolobular)                                                                                              absent                                                    absent                                                                                                                                                                                                                 present (intralobular)                                                                                                          N/A                                                                                            absent                                                                                                                            absent                        absent                                                          absent

  **Portal infiltration**                                                    plasma cell infiltrate                                                                                                                                    absent                                                                                                                        absent                                                       absent                                                                                                               absent                                                    absent                                                                                                                                                                                                                 Plasma cell infiltrate                                                                                                          N/A                                                                                            absent                                                                                                                            mixed cell infiltrate         absent                                                          plasma cell infiltrate

  ***CD68***                                                                 62                                                                                                                                                        45                                                                                                                            N/A                                                          91                                                                                                                   73                                                        74                                                                                                                                                                                                                     48                                                                                                                              N/A                                                                                            59                                                                                                                                78                            N/A                                                             75

  ***Specific therapy for HLH***                                             Yes                                                                                                                                                       Yes                                                                                                                           Yes                                                          Yes                                                                                                                  No                                                        No                                                                                                                                                                                                                     No                                                                                                                              Yes                                                                                            No                                                                                                                                Unknown                       No                                                              No

  ***Time from hospital admission to HLH therapy initiation*, *days***       13                                                                                                                                                        6                                                                                                                             2                                                            No HLH\                                                                                                              No HLH\                                                   No HLH\                                                                                                                                                                                                                No HLH\                                                                                                                         7                                                                                              No HLH\                                                                                                                           No HLH\                       No HLH\                                                         No HLH\
                                                                                                                                                                                                                                                                                                                                                                                                                                  Spec. Rx                                                                                                             Spec. Rx                                                  Spec. Rx                                                                                                                                                                                                               Spec. Rx                                                                                                                                                                                                                       Spec. Rx                                                                                                                          Spec. Rx                      Spec. Rx                                                        Spec. Rx

  ***Therapy received***                                                     Etoposide and corticosteroids + Antibiotics (ciprofloxacin) + gancyclovir                                                                                 Etoposide and corticosteroids + empirical gancyclovir and antibiotics                                                         Etoposide and steroids + antibiotics                         Corticosteroids and IL-1 antagonists (for the underlying lupus) + antibiotics                                        Antibiotics only                                          Antibiotics (imipenem/cilastatin) + cyclosporin for PRCA                                                                                                                                                               Corticosteroids for Evans Syndrome                                                                                              Plasmapheresis and corticosteroids + antibiotics                                               Corticosteroids and cyclosporin for underlying disease + gancyclovir                                                              Unknown                       None                                                            Corticosteroids for AIH

  case interpreted as concomitant DILI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  ***Outcome***                                                              Progressive improvement; discharged after 30 days ICU; chronic slight AST/ALT elevation. Liver biopsy 1 year after discharge: signs of hemophagocytosis   Death due to MOF and DIC 12 days after presentation                                                                           Death 10 days after hospitalisation due to MOF               Progressive worsening with MOF; death 26 days after presentation and hospitalisation                                 Rapid remission; discharged after 7 days; no recurrence   Progressive worsening with development of jaundice and anasarca; therapy offered on histological confirmation of HLH, but patient chose not to be treated. Death 30 days after presentation (5 days after diagnosis)   Remission on steroids; no recurrence                                                                                            Death 16 days after presentation (cardiac sudden death during ongoing MOF)                     Spontaneous bacterial peritonitis and jaundice associated with hepatic encephalopathy grade 2. Death 36 days after presentation   Unknown                       Progressive improvement, but still cholestatic after 3 months   Remission
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In all cases the records showed a detailed workup of all relevant differential diagnoses, including sepsis (microbiology workup) and evaluation of the anemia (Coombs test, LDH, haptoglobin, unconjugated bilirubin, schistocytes).

Signs of sinusoidal hemophagocytosis detected on liver biopsy were rare in our center, being this finding seen in approximately 0.3% of all liver biopsies performed in the study period (n = 3855). However, seven of the cases were diagnosed in the last two years suggesting an increased awareness of HLH and the association of this pathologic finding to HLH.

Reasons for liver biopsy in our patients were increased acute or chronic liver function tests (n = 8), or fever of unknown origin associated with alteration of liver function tests.

Clinical and laboratory features of patients meeting the HLH diagnostic criteria {#sec009}
--------------------------------------------------------------------------------

Six patients (three males; median age 71 years; IQR 32; range 22--74) met the diagnostic criteria for HLH ([Table 2](#pone.0226899.t002){ref-type="table"}); in three of them (50%), the HLH diagnosis was made after performing transjugular liver biopsy, upon the finding of sinusoidal hemophagocytosis. Interestingly, in two cases (case 6 and 7) the Hscore was low- namely 119 and 127- reflecting a \<10% risk of HLH.

All patients but one were severely ill on admission, and all but one (patient 6, who was also not severely ill) had underlying chronic diseases: two had autoimmune diseases on chronic immunosuppressive therapy (ulcerative colitis in one; systemic lupus erythemathodes and secondary antiphospholipid syndrome in one) and three had hematological diseases (Chronic lymphocitic leukemia and Evans Syndrome in one; anaplastic lymphoma--that was diagnosed during the hospitalization- in one, and pure white cell aplasia in one). All patients but one (patient 9) presented with high fever, in four cases associates with pancytopenia. In three patients bone marrow biopsy was performed and did not show signs of hemophagocytosis. The most common diagnosis on admission was sepsis.

All cases showed increase in LFTs; usually, transaminases were moderately increased (2--10 times the upper limit of normality). All patients showed hypoalbuminemia. Jaundice was present in three patients on admission and developed in all cases but one during the course of the hospitalisation.

A possible infectious trigger for HLH was identified in 5 patients.

The median time interval between the hospital admission and liver biopsy was 11 days (IQR 18; range 2 to 25). The time from hospital admission to the histological diagnosis was significantly shorter in patients presenting with higher ferritin and higher alkaline phosphatase (ALP) (5 days vs. 21 days in median; p = 0.03).

All patients received antibiotics, two of them received additionally antivirals treatment (i.e. ganciclovir) aimed at controlling a suspected (in one case) or diagnosed (in another case) underlying CMV infection. Five patients received immunosuppressants (steroids and etoposide in three, steroids and anti-IL1 in one, cyclosporin in one). The immunosuppressive therapy was ongoing since the hospitalization in three cases, while a specific therapy was started in three patients respectively 2, 6 and 13 days after the admission, as soon as the report of the liver biopsy became available (on the same day or on the following day). Four patients (67%) died during the hospitalization, while two (case 2 and 6) recovered. One of the survivors (case 2) showed a chronic slight elevation of cholestasis enzymes on follow-up. A second liver biopsy was obtained one year after the first admission and showed again signs of sinusoidal hemophagocytosis.

Clinical and laboratory features of patients not meeting the HLH diagnostic criteria {#sec010}
------------------------------------------------------------------------------------

Six patients (4 males; median age 68 years; IQR 33; range 24--81) did not meet the diagnostic criteria for HLH ([Table 2](#pone.0226899.t002){ref-type="table"}). The laboratory parameters on admission (AST, ALT, ALP, GGT, albumin, INR, creatinine, hemoglobin, platelet count) were similar to those of patients fulfilling the diagnostic criteria of HLH, and despite similar signs and symptoms, patients were less severely ill (only one patient was initially admitted to the ICU due to critical illness). Median Hscore was 149 points (IQR 75; range 90--190), with in median 3 criteria fulfilled (IQR 2; range 1--4). Similarly to patients fulfilling the diagnostic criteria of HLH, all patients but one had underlying chronic diseases: autoimmune conditions in three, hematological malignancy in one, and alcoholic cirrhosis with portal hypertension (large varices on endoscopy) in one; only this latter patient was severely ill on admission. One patient had a suspected hemolytic-uremic syndrome and one had a CMV infection as potential infectious triggers of their severe inflammatory status. In one case (Patient 8) in addition to sinusoidal hemophagocytosis findings on liver biopsy (fifth positive criterion for HLH), there were also signs suggesting autoimmune hepatitis. Bone marrow biopsy did not show signs of HLH. Furthermore, this patient showed a fast response to corticosteroids. The diagnosis of HLH was then considered unlikely. Three patients (one previously diagnosed with cirrhosis-case 3, and one with signs of advanced chronic liver disease on liver biopsy- case 4) had clinically evident, moderate ascites on presentation. All patients showed hypoalbuminemia and all patients were jaundiced on admission. Increase in transaminases was usually mild to moderate and very elevated values of AST or ALT (\>15 times the upper limit of normality) were observed only in the patient diagnosed with autoimmune hepatitis (case 12) \[[@pone.0226899.ref023]\]. Two patients (33%), both with underlying advanced liver disease, became critically ill during the hospitalization and died. Four patients, including the two who died, received steroids as part of their treatment.

Histological findings of liver biopsy, correlation with clinical presentation and outcome {#sec011}
-----------------------------------------------------------------------------------------

Two patients with a definite diagnosis of HLH and two not fulfilling the criteria for HLH showed sinusoidal dilatation. None of the patients with HLH had fibrosis, while three of the patients not fulfilling the criteria for HLH showed some extent of liver fibrosis (non-septal in one, septal in two). Three patients with HLH showed centrolobular necrosis and one patient without HLH showed intralobular necrosis. A plasma cell infiltrate was observed in one patient with HLH, and in two patients without HLH; one additional patient without HLH showed mixed inflammatory cells infiltrate.

As far as the sinusoidal hemophagocytosis findings, histology and immunohistochemistry showed similar findings, irrespective of whether a final diagnosis of HLH was made.

[Fig 1](#pone.0226899.g001){ref-type="fig"} shows representative images HE staining revealed mononuclear cells infiltration in the portal tract and sinusoids.

![Liver biopsy showing signs of sinusoidal hemophagocytosis (arrows).\
Panel A and Panel B: HE (100x) patient with HLH syndrome. Panel C: HE (100x) patient fulfilling 3 diagnostic criteria of HLH syndrome. Panel D. IHC for CD68 (20x) showing multiple cells expressing CD68.](pone.0226899.g001){#pone.0226899.g001}

Immunohistochemistry showed numerous CD68 positive macrophages, which, on HE staining, presented clear signs of hemophagocytosis. An exception was represented by a patient (case 12) presenting with features of autoimmune hepatitis associated with sinusoidal hemophagocytosis.

Increased AST on presentation positively correlated with the number of foci of hemophagocytosis on liver biopsy (Spearman's rho: 0.773, p = 0.015) ([Fig 2](#pone.0226899.g002){ref-type="fig"}).

![Correlation of AST and number of sinusoidal hemophagocytosis foci; observed at 20x on liver biopsy (Spearman's Rho r = 0.773, p = 0.015).](pone.0226899.g002){#pone.0226899.g002}

Mortality in patients with sinusoidal hemophagocytosis {#sec012}
------------------------------------------------------

As discussed above, in the present series of sinusoidal hemophagocytosis on liver biopsy, 50% (n = 6) died, mostly within one month since hospital admission (median 12 days; IQR 21; range 10 to 36). Irrespective of whether a final diagnosis of HLH was determined during admission, all patients who died, had severe underlying chronic diseases, and in all cases at admission a typical presentation including high fever, hepato-splenomegaly and bicytopenia was present ([Table 2](#pone.0226899.t002){ref-type="table"}). With the limitation of a small number of events, none of the laboratory findings was statistically associated with fatal outcome, even if ferritin tended to be higher in patients who were deceased in comparison to survivors (median: 25'516 vs.10'536 μg/L).

Discussion {#sec013}
==========

Hemophagocytic lymphohistiocytosis (HLH), or haemophagocytic syndrome is a life-threatening disease with a reported mortality of over 50% \[[@pone.0226899.ref003]\], belonging to the so-called "cytokine storm syndromes". In HLH, following a strong immunological stimulus, the uncontrolled proliferation of activated macrophages and lymphocytes leads to the secretion of a massive amount of inflammatory cytokines, which are thought to explain the organ damage \[[@pone.0226899.ref001]\]\]. In patients with infection-triggered HLH, initial symptoms are non-specific, and the diagnosis of HLH can be challenging. \[[@pone.0226899.ref001], [@pone.0226899.ref004]\]\]. Patients with HLH, however, cannot control the hyperinflammatory response which, if left untreated, is often fatal \[[@pone.0226899.ref001], [@pone.0226899.ref002], [@pone.0226899.ref024]\].

Despite its rarity, HLH is observed in up to 1% of patients with hematologic malignancy \[[@pone.0226899.ref024]\]\] and has a dismal prognosis if left untreated. Clinical suspicion is key to drive the work-up recommended to diagnose HLH, which includes standard laboratory tests, specific tests and biopsy of organs that can be affected by the hemophagocytosis process.

In the largest series published so far in adult patients with HLH, alteration of LFTs is almost invariably observed \[[@pone.0226899.ref012], [@pone.0226899.ref025]\]\], and AST/ALT elevation is considered among the criteria used to calculate the Hscore \[[@pone.0226899.ref022]\]\]. Despite this, few cases of HLH presenting mainly as liver disease have been described in the literature \[[@pone.0226899.ref013], [@pone.0226899.ref014], [@pone.0226899.ref016], [@pone.0226899.ref025]\], and the significance of signs of hemophagocytosis observed in liver biopsy in patients not fulfilling the classical diagnostic criteria for HLH is currently unknown.

It has been previously reported that findings of hemophagocytosis in bone marrow aspirates is frequent even in subjects without HLH \[[@pone.0226899.ref026]\]. In our study focusing on liver biopsy, signs of hemophagocytosis were rarely found among all reviewed specimens. Our findings might suggest that the liver is less often involved, or later affected in the immunological processes leading to HLH. Given that liver biopsy is not frequently performed on suspicion of HLH, further studies with a larger number of patients would be valuable to confirm our findings. On the other hand, sinusoidal hemophagocytosis might be overlooked if not specifically sought; we observed an increase in the number of diagnosed cases at our center in the last two years, supporting an increased awareness for this sign and for HLH. It should be underlined that the finding of sinusoidal hemophagocytosis does not imply a diagnosis of HLH as this finding is considered non-specific and is present in other conditions characterized by immune activation such as sepsis \[[@pone.0226899.ref020]\]. In our series, half of the cases showing sinusoidal hemophagocytosis fulfilled the diagnostic criteria of HLH. Importantly, liver biopsy led to the definitive diagnosis of HLH in three patients in whom clinical and laboratory HLH diagnosis criteria were not otherwise fulfilled. It has to be taken into account that the diagnostic performance of Hscore in adults is debated \[[@pone.0226899.ref027]\]. However, a correct diagnosis ruling-out or ruling-in HLH is key, on one side to avoid immunosuppression when it is not needed, on the other side since newer therapies such as interferon gamma inhibitors may make a difference to outcomes in the future. The finding of sinusoidal hemophagocytosis can be considered an important diagnostic feature to be searched in adults upon clinical suspicion of HLH and indeterminate laboratory findings, and we suggest that transjugular liver biopsy can be considered as a further diagnostic tool to provide an additional indicator supporting HLH diagnosis and complementing clinical acumen and laboratory tests. In this regard, it should be underlined that transjugular liver biopsy is a safe procedure, even in patients with severe thrombocytopenia and coagulopathy \[[@pone.0226899.ref028]\]. We acknowledge that since liver biopsy is not routinely performed in patients already diagnosed with HLH at our center, we cannot provide data regarding the sensitivity of liver biopsy in the context of HLH, meaning that we do not know if patients with HLH might show negative results (no sinusoidal hemophagocytosis) on liver biopsy.

As for the patients showing sinusoidal hemophagocytosis but not fulfilling the diagnostic criteria for HLH, the clinical presentation was usually less severe as compared to patients fulfilling the criteria for HLH. On the other hand, both groups shared several features, including similar values of laboratory tests, and presence of underlying chronic diseases frequently associated with HLH \[[@pone.0226899.ref001], [@pone.0226899.ref006], [@pone.0226899.ref007]\]. This suggests that sinusoidal hemophagocytosis in the absence of HLH might indicate uncontrolled hepatic/systemic inflammation, leading to clinical features closely resembling HLH.

Regarding liver-related findings, most of the patients showed a mild to moderate increase of AST/ALT. A novel, interesting finding of the present study is that AST at presentation closely correlated with the severity of histological signs of hemophagocytosis, suggesting that monitoring AST on treatment might help in evaluating the inflammatory activityitself, and potentially in assessing treatment efficacy. Confirmation of this correlation in a larger number of patients would be of interest.

All our patients showed hypoalbuminemia. In our view, even if this is a non-specific finding, it should be included among those appearing in adult HLH, similarly to what is already done in children suspected of HLH\[[@pone.0226899.ref029]\].

Similarly to what occurs in patients with sepsis, jaundice (total bilirubin \> 50μmol/L) was present at admission or developed over the course of the hospital admission in all patients with signs of hemophagocytosis but one, likely reflecting the effects of pro-inflammatory cytokines on several steps of bile flow (down regulation of bile acid transporters \[[@pone.0226899.ref030]\]; oxidative stress leading to the inhibition of cAMP-dependent transport function \[[@pone.0226899.ref031]\] eventually leading to intrahepatic cholestasis.

Interestingly, the number of CD68 macrophages on histology did not correlate with the number of positive foci. Consequently, the number of CD68 positive cells does not seem useful to demonstrate liver involvement in hemophagocytosis, which relies mostly on haematoxylin and eosin.

In agreement with previous reports regarding a very high mortality in patients with HLH \[[@pone.0226899.ref001], [@pone.0226899.ref012], [@pone.0226899.ref024]\], four patients with HLH included in our series died, all of them within approximately one month after being hospitalized. Similarly to the report by Li et al \[[@pone.0226899.ref012]\], all patients who died in our series presented typically with high fever, hepato-splenomegaly and bicytopenia, which should be considered as ominous prognostic signs. In addition, two patients with sinusoidal hemophagocytosis not fulfilling the diagnostic criteria for HLH died.

These patients had either a known cirrhosis or advanced liver disease on liver biopsy and presented with ascites. This suggest that in patients with cirrhosis---in whom immune-response is altered \[[@pone.0226899.ref032], [@pone.0226899.ref033]\]---hemophagocytosis likely indicates a particularly severe inflammatory activation, which might explain a very severe acute- on- chronic liver failure.

A novel observation in our series concerns the finding of signs of hemophagocytosis in a follow-up liver biopsy obtained one year after discharge in the patient surviving a first episode of HLH (triggered by viral and bacterial infection; case 2). Interestingly, bone marrow biopsy at the time of first diagnosis was negative. To our knowledge, chronic secondary hemophagocytosis in the liver has never been reported so far. Whether this might be linked to a genetic component with a liver-specific behavior is currently unknown.

In conclusion, signs of hemophagocytosis on liver biopsy can be found in patients fulfilling or not the diagnostic criteria for HLH. Mortality in HLH was very high in this series. In subjects in whom HLH is suspected transjugular liver biopsy might be considered since it can provide findings supporting a HLH diagnosis complementing clinical acumen and laboratory tests. Patients not fulfilling the diagnostic criteria for HLH showed similar risk factors and triggers as patients with HLH and two of them had a fatal outcome, suggesting that sinusoidal hemophagocytosis in the absence of HLH might still indicate uncontrolled hepatic and systemic inflammation, leading to clinical features closely resembling HLH. Signs of hemophagocytosis on histology in patients with a history of chronic liver disease seem to be an ominous prognostic sign even in the absence of HLH. Irrespective of whether a diagnosis of HLH is eventually made, all patients with suspected HLH and patients with findings of sinusoidal hemophagocytosis on liver biopsy should receive an extensive work-up aimed at identifying possible triggers amenable to treatment.
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